Hakeam A Hakeam1, Hala Alsahli2, Lama Albabtain2, Shahad Alassaf2, Zainab Al Duhailib3, Sahar Althawadi4. 1. Pharmaceutical Care, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia. Electronic address: hakeam@kfshrc.edu.sa. 2. College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia. 3. Critical Care Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. 4. Pathology and Laboratory Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Abstract
INTRODUCTION: Antimicrobial treatments for carbapenem-resistant Enterobacteriaceae (CRE) bacteremia are limited, with colistin-based regimens being a primary therapy. Ceftazidime-avibactam is an emerging treatment for various CRE infections. Our study aimed to assess ceftazidime-avibactam effectiveness compared with colistin in patients with CRE bacteremia. METHODS: This retrospective, multi-centre study included adult patients with CRE bacteremia treated with ceftazidime-avibactam or colistin, between September 1, 2017 and December 1, 2020, at two tertiary centres in Saudi Arabia. The risk of 14-day mortality was compared between recipients of ceftazidime-avibactam versus colistin, using Cox multivariable regression, adjusted for Pitt score, Charlson index score, and treatment with chemotherapy and immunosuppressive agents. RESULTS: In total, 61 patients were enrolled; 32 received ceftazidime-avibactam, and 29 received colistin. The adjusted risk for 14-day mortality was lower in the ceftazidime-avibactam group than the colistin group (hazard ratio [HR] 0.32; 95% confidence interval [CI] 0.10-0.99; p = 0.049), while the crude 14-day mortality did not differ between the two antibiotics (HR, 0.59; 95% CI 0.21-1.66; p = 0.32). The clinical success rate was higher with the use of ceftazidime-avibactam versus colistin (46.8% versus 20.4%, respectively; p = 0.047). CONCLUSION: Ceftazidime-avibactam was associated with a lower risk of 14-day mortality than colistin in patients with CRE bacteremia.
INTRODUCTION: Antimicrobial treatments for carbapenem-resistant Enterobacteriaceae (CRE) bacteremia are limited, with colistin-based regimens being a primary therapy. Ceftazidime-avibactam is an emerging treatment for various CRE infections. Our study aimed to assess ceftazidime-avibactam effectiveness compared with colistin in patients with CRE bacteremia. METHODS: This retrospective, multi-centre study included adult patients with CRE bacteremia treated with ceftazidime-avibactam or colistin, between September 1, 2017 and December 1, 2020, at two tertiary centres in Saudi Arabia. The risk of 14-day mortality was compared between recipients of ceftazidime-avibactam versus colistin, using Cox multivariable regression, adjusted for Pitt score, Charlson index score, and treatment with chemotherapy and immunosuppressive agents. RESULTS: In total, 61 patients were enrolled; 32 received ceftazidime-avibactam, and 29 received colistin. The adjusted risk for 14-day mortality was lower in the ceftazidime-avibactam group than the colistin group (hazard ratio [HR] 0.32; 95% confidence interval [CI] 0.10-0.99; p = 0.049), while the crude 14-day mortality did not differ between the two antibiotics (HR, 0.59; 95% CI 0.21-1.66; p = 0.32). The clinical success rate was higher with the use of ceftazidime-avibactam versus colistin (46.8% versus 20.4%, respectively; p = 0.047). CONCLUSION:Ceftazidime-avibactam was associated with a lower risk of 14-day mortality than colistin in patients with CRE bacteremia.
Authors: Basem M Alraddadi; Emily L G Heaphy; Yamama Aljishi; Waleed Ahmed; Khalid Eljaaly; Hanan H Al-Turkistani; Abeer N Alshukairi; Mohammed O Qutub; Kholoud Alodini; Roaa Alosaimi; Waseem Hassan; Dalya Attalah; Rakan Alswaiel; Mohammed F Saeedi; Mohammed A Al-Hamzi; Lama K Hefni; Reem S Almaghrabi; Mushira Anani; Abdulhakeem Althaqafi Journal: BMC Infect Dis Date: 2022-06-13 Impact factor: 3.667
Authors: Thamer A Almangour; Leen Ghonem; Ahmad Aljabri; Alya Alruwaili; Mohammed Al Musawa; Nader Damfu; Mesfer S Almalki; Majda Alattas; Hossam Abed; Doaa Naeem; Nawaf Almalki; Abdullah A Alhifany Journal: Infect Drug Resist Date: 2022-01-23 Impact factor: 4.003